ES2169060T3 - Agentes citotoxicos de longitud de onda especifica. - Google Patents

Agentes citotoxicos de longitud de onda especifica.

Info

Publication number
ES2169060T3
ES2169060T3 ES94115192T ES94115192T ES2169060T3 ES 2169060 T3 ES2169060 T3 ES 2169060T3 ES 94115192 T ES94115192 T ES 94115192T ES 94115192 T ES94115192 T ES 94115192T ES 2169060 T3 ES2169060 T3 ES 2169060T3
Authority
ES
Spain
Prior art keywords
tissues
specific
cells
wave length
cytotoxic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94115192T
Other languages
English (en)
Inventor
Julia G Levy
David Dolphin
Jack K Chow
Ethan Sternberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2169060T3 publication Critical patent/ES2169060T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

UN GRUPO DE HIDRO-MONOBENZOPORFIRINAS "PORFIRINAS VERDES" (GP) QUE TIENEN UNA ABSORCION MAXIMA DEL ORDEN DE 670 NOMETROS ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES O CONDICIONES QUE ESTEN SUJETAS A TRATAMIENTO CON UN DERIVADO DE HEMATOPORFIRINA (HPD) EN PRESENCIA DE LUZ, O PARA TRATAR VIRUS, CELULAS Y TEJIDOS GENERALMENTE PARA DESTRUIR OBJETIVOS INDESEADOS. EL USO DE GP DE LA INVENCION PERMITE QUE LA IRRADICION USE LONGITUDES DE ONDA DIFERENTES DE AQUELLAS ABSORBIDAS POR LA SANGRE. EL GP DE LA INVENCION PUEDE TAMBIEN SER CONJUGADO CON LIGANTES ESPECIFICOS PARA EL RECEPTOR O INMOGLOBULINAS ESPECIFICAS O FRAGMENTOS CONSIGUIENTES PARA ENCUADRAR TEJIDOS ESPECIFICOS O CELULAS PARA EL TRATAMIENTO POR RADIACION. EL USO DE ESTOS MATERIALES PERMITE QUE SE USEN NIVELES INFERIORES DE MEDICAMENTO, EVITANDO ASI REACCIONES SECUNDARIAS QUE PUEDAN DESTRUIR TEJIDOS NORMALES.
ES94115192T 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica. Expired - Lifetime ES2169060T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,161 US4920143A (en) 1987-04-23 1988-07-19 Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Publications (1)

Publication Number Publication Date
ES2169060T3 true ES2169060T3 (es) 2002-07-01

Family

ID=22826617

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94115192T Expired - Lifetime ES2169060T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica.
ES89307281T Expired - Lifetime ES2080745T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES89307281T Expired - Lifetime ES2080745T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica

Country Status (10)

Country Link
US (1) US4920143A (es)
EP (2) EP0641796B1 (es)
AT (2) ATE209650T1 (es)
AU (1) AU638675B2 (es)
CA (1) CA1339927C (es)
DE (3) DE68924215T2 (es)
ES (2) ES2169060T3 (es)
GR (1) GR3017426T3 (es)
LU (1) LU90718I2 (es)
NL (1) NL300037I2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
WO1990015059A1 (en) * 1989-06-07 1990-12-13 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5435307A (en) * 1991-03-29 1995-07-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Surface fluorescent monitor
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
US6890555B1 (en) * 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2097280A1 (en) * 1992-06-01 1993-12-02 Sandor G. Vari Apparatus and method of use for a photosensitizer enhanced fluorescence based bipsy needle
CA2142711A1 (en) * 1992-08-17 1994-03-03 Anna M. Richter Method for destroying or inhibiting growth of unwanted cells or tissues
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
DE19514088A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5952329A (en) * 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
WO1999013943A1 (en) 1996-03-05 1999-03-25 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5693789A (en) * 1996-04-10 1997-12-02 Abbott Laboratories Process for the preparation of a protoporphyrin
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
ES2171022T3 (es) * 1997-05-07 2002-08-16 Quadra Logic Tech Inc Esteres de etilenglicol de derivados de monohidrobenzoporfirinas como agentes fotoactivos.
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
EP0983272B1 (en) * 1997-05-07 2003-10-29 University Of British Columbia A new class of benzoporphyrin derivative photoactive compounds
WO1999004857A1 (de) 1997-07-28 1999-02-04 Novartis Ag Vorrichtung und verfahren zum bestrahlen eines auges eines patienten für eine photodynamische therapie
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
JP4643004B2 (ja) 1998-01-06 2011-03-02 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU4139600A (en) 1999-04-14 2000-11-14 University Of British Columbia, The 1,3-dipolar cycloadditions to polypyrrolic macrocycles
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US6750037B2 (en) * 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
JP2003528926A (ja) 2000-03-24 2003-09-30 ノバルティス アクチエンゲゼルシャフト 新血管形成の改善された処置
US7282215B2 (en) 2000-05-08 2007-10-16 The University Of British Columbia Supports for photosensitizer formulations
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
DE60219627T2 (de) 2001-06-04 2008-02-07 The General Hospital Corp., Boston Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
EP1465590B1 (en) * 2001-11-02 2008-03-26 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
JP2005513001A (ja) * 2001-11-09 2005-05-12 キュー エル ティー インク． 脱毛治療のための光力学療法
ATE336266T1 (de) * 2002-06-21 2006-09-15 Adair Edwin Lloyd Anwendung von metalloporphyrinen zur behandlung von arteriosklerose
US20060258629A1 (en) * 2002-10-18 2006-11-16 Freeman William R Photodynamic therapy for ocular neovascularization
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
BRPI0518198B8 (pt) 2004-10-29 2021-06-22 Cerus Corp método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit
SG189745A1 (en) 2008-04-09 2013-05-31 Cerus Corp Improved quenching methods for red blood cell pathogen inactivation
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
AU2012205410A1 (en) 2011-01-13 2013-08-01 Qlt Inc. Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
EP2872178A1 (en) 2012-07-11 2015-05-20 Dermira, Inc. Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
EP3044236A2 (en) 2013-09-12 2016-07-20 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3056396A1 (en) 2017-03-14 2018-09-20 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
JPS60500132A (ja) * 1982-09-27 1985-01-31 ヘルス・リサーチ・インコーポレーテッド 腫瘍の診断および治療のための精製されたヘマトポルフイリン誘導体ならびにその方法
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents

Also Published As

Publication number Publication date
DE68929351T2 (de) 2002-05-08
DE68929351D1 (de) 2002-01-10
AU3825889A (en) 1990-02-08
CA1339927C (en) 1998-06-23
DE68924215T2 (de) 1996-02-15
NL300037I2 (nl) 2001-08-01
DE68924215D1 (de) 1995-10-19
EP0641796A1 (en) 1995-03-08
EP0352076A3 (en) 1991-07-17
DE10199008I1 (de) 2003-06-12
AU638675B2 (en) 1993-07-08
GR3017426T3 (en) 1995-12-31
EP0352076A2 (en) 1990-01-24
DE10199008I2 (de) 2004-10-14
ATE127696T1 (de) 1995-09-15
ES2080745T3 (es) 1996-02-16
EP0641796B1 (en) 2001-11-28
EP0352076B1 (en) 1995-09-13
US4920143A (en) 1990-04-24
LU90718I2 (fr) 2001-03-01
ATE209650T1 (de) 2001-12-15
NL300037I1 (nl) 2001-03-01

Similar Documents

Publication Publication Date Title
ES2080745T3 (es) Agentes citotoxicos de longitud de onda especifica
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
JP4662631B2 (ja) 光エネルギを用いた色素沈着組織の治療装置
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
EP0947222B1 (en) Method of activating photosensitive agents
US20050004510A1 (en) Noninvasive vascular therapy
ES2055735T3 (es) Agentes citotoxicos con longitud de onda especifica.
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
KR20010083045A (ko) 치료제의 다광자 광활성화를 위한 개선된 방법 및 장치
EP0425566A4 (en) New photosensitizing agents
PT933995E (pt) Metodo para tratamento de lesao endotelial
Biolo et al. Photodynamic therapy of B16 pigmented melanoma with liposome‐delivered Si (IV)‐naphthalocyanine
EP1120119A4 (en) REMEDIES FOR PHOTOCHEMOTHERAPY
WO2000041725A3 (en) Therapeutic compositions for metabolic bone disorders or bone metastases
WO1992000106A3 (en) Method of treatment and compositions therefore
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
McKenzie How may external and interstitial illumination be compared in laser photodynamic therapy?
Mimura et al. Cooperative Clinical Trial of Photodynamic Therapy for Early Gastric Cancer With Photofrin Injection® and YAG‐OPO Laser
Powers Cationic dyes with mitochondrial specificity for phototherapy of malignant tumors
US6586419B1 (en) Phototherapeutic inactivation of ocular viruses
Nyamekye Vascular and other non-tumour applications of photodynamic therapy
RU96107054A (ru) Способ фотодинамической терапии злокачественных новообразований
RU2229906C2 (ru) Способ волновой терапии
ES2022327B3 (es) Camara de irradiacion para sistema de tratamiento de pacientes por fotoactivacion
RU2113254C1 (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641796

Country of ref document: ES